Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Knee replacement is highly successful for treating severe arthritis. There are 100,000 people who undergo knee replacement surgery every year in the UK, with numbers set to rise significantly in future.

It remains however a painful procedure with nearly half of patients reporting severe pain post-operatively. Currently pain control is provided by injecting a local anaesthetic of bupivacaine hydrochloride around the knee during surgery providing good pain relief for 12 to 24 hours. However, patients typically experienced the worst pain the next morning when they are encouraged to bend their knee and get out of bed.

Researchers at the Universities of Oxford and Leeds developed the SPAARK (Study of Peri-Articular Anaesthetic for Replacement of the Knee) Trial, to test whether liposomal bupivacaine, a post-operative pain treatment widely used in the USA would be more effective at managing the pain compared to current treatments. The findings have been published in JAMA.

Lead author Thomas Hamilton, Academic Clinical Lecturer in Trauma and Orthopaedic Surgery at NDORMS said: "We found that liposomal bupivacaine injected at the surgical side during knee replacement did not improve post-operative recovery, compared to those receiving bupivacaine hydrochloride alone. We saw no difference in Quality of Recovery score at 72 hours, nor pain assessed using pain visual analogue scale area under the curve at 6 to 72 hours. The results of this study do not support the use of peri-articular liposomal bupivacaine for knee replacement ."

Prof Hemant Pandit (Professor of Orthopaedic Surgery, University of Leeds and University of Oxford) senior author and chief investigator of the study added: "This is the largest randomised controlled trial in the world to assess the effectiveness of liposomal bupivacaine in achieving superior pain relief in patients undergoing a knee replacement. The study results are timely and demonstrate that there is no additional benefit in the pain relief experienced by patients receiving Liposomal Bupivacaine and therefore the drug's use in routine NHS practice cannot be justified."

The research was funded by a grant from the NIHR Research for Patient Benefit Programme with the study drug (and additional funding) provided by Pacira Pharmaceuticals.

Similar stories

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.

Study reveals new evidence on rare blood-clotting condition after covid-19 vaccination

Researchers from NDORMS at the University of Oxford have investigated claims that some adenovirus-based COVID-19 vaccines increase the risk of rare blood clots compared to their mRNA-based counterparts.

NDORMS contributes to new UK research to tackle monkeypox outbreak

The UK’s efforts to tackle the monkeypox outbreak will receive a huge boost with the creation of a new research consortium and a new study to study vaccine effectiveness.